Form 4: VYNE CFO Tyler Zeronda Reports Tax-Related Stock Sale

VYNE Therapeutics Inc.'s Chief Financial Officer, Tyler Zeronda, reported a disposition of 7,858 common shares to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Tyler Zeronda, Chief Financial Officer of VYNE Therapeutics Inc., reported a transaction on December 31, 2025.
• The transaction involved the disposition of 7,858 shares of common stock at a price of $0.5801 per share.
• This disposition was a mandatory withholding by the issuer to satisfy tax requirements associated with the vesting of restricted stock units.
• Following this transaction, Zeronda beneficially owns 103,795 shares of common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary disposition of shares for tax withholding purposes, which is neutral in terms of sentiment. It reflects standard equity compensation practices rather than a strategic move.

Future Outlook

NA

Industry Context

This is a routine insider transaction related to equity compensation and tax obligations, common across all industries for executives receiving restricted stock units. It does not reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, non-discretionary transaction for tax purposes, not indicative of a change in management's confidence or company fundamentals.

Key Dates

Keywords

VYNE Therapeutics, VYNE, Tyler Zeronda, CFO, Form 4, Insider Transaction, Stock Disposition, Tax Withholding, Restricted Stock Units, Equity Compensation